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We investigated the impact of chronic hypercorticosteronemia (due to neonatal monosodium L-glutamate, MSG, and treatment)
on liver oxidative stress (OS), inflammation, and carbohydrate/lipid metabolism in adult male rats. We evaluated the peripheral
concentrations of several metabolic and OS markers and insulin resistance indexes. In liver we assessed (a) OS (GSH and protein
carbonyl groups) and inflammatory (IL-1b, TNFa, and PAI-1) biomarkers and (b) carbohydrate and lipid metabolisms. MSG rats
displayed degenerated optic nerves, hypophagia, low body and liver weights, and enlarged adipose tissue mass; higher peripheral
levels of glucose, triglycerides, insulin, uric acid, leptin, corticosterone, transaminases and TBARS, and peripheral and liver insulin
resistance; elevated liver OS, inflammation markers, and glucokinase (mRNA/activity) and fructokinase (mRNA). Additionally,
MSG liver phosphofructokinase-2, glucose-6-phosphatase (mRNA and activity) and glucose-6-phosphate dehydrogenase, Chrebp,
Srebp1c, fatty acid synthase, and glycerol-3-phosphate (mRNAs) were increased. In conclusion adultMSG rats developed an insulin-
resistant state and increased OS and serious hepatic dysfunction characterized by inflammation and metabolic signs suggesting
increased lipogenesis.These features, shared by bothmetabolic and Cushing’s syndrome human phenotypes, support that a chronic
glucocorticoid-rich endogenous environment mainly impacts on hepatic glucose cycle, displacing local metabolism to lipogenesis.
Whether correcting the glucocorticoid-rich environment ameliorates such dysfunctions requires further investigation.
1. Introduction
Several studies have described the effects of neonatal mono-
sodium L-glutamate (MSG) administration in rodents [1,
2]. It is openly accepted that MSG treatment induces mor-
phological, behavioral, and endocrine abnormalities, such
as growth disturbances, hyperadiposity, and hypogonadism
[1, 3]. Other studies reported severe loss of catecholaminergic
and peptidergic neurons in the retina and the hypothalamic
arcuate nucleus (ARC) [3–5]. This neuronal loss alters sev-
eral endocrine-metabolic functions, such as energy balance
[6–8] and anterior pituitary hormone secretion [9, 10]. A
conspicuous effect of MSG-induced hypothalamic damage is
enhanced overall response of median eminence neurons
terminals [9, 10]. The extensive brain damage has been used
to explain several of the altered neuroendocrine functions in
this model [5, 11]. ARC plays a pivotal role in regulation of
energy storage and expenditure, and adipose tissue leptin
secretion and hypothalamic leptin signaling system play key
roles for maintaining homeostasis [12].
Among others, neonatalMSG treatment also affects white
adipocyte function. MSG rats develop hyperleptinemia due
to both enlarged adipose tissue mass and adipocyte size [13].
Moreover, chronic excess of endogenous glucocorticoids
(GC) has been considered a main factor of the hypertrophic
adiposity developed by the adult MSG rat [14]. Indeed, MSG
animals are partly refractory to leptin inhibition (leptin
resistance) of food intake and body weight gain [15] and,
importantly, to the leptin negative control on adrenocortical
function [16–18]. Moreover, the adult MSG rat phenotype is
also characterized by an enhanced proinflammatory periph-
eral environment [19].
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Because of the overall endocrine-metabolic characteris-
tics, namely, hypercorticosteronemia and adipose tissuemass
excess, the MSG rat is an excellent experimental model for
basic investigation of different dysfunctions representative
of the human Cushing’s syndrome (hypothalamic obesity)
phenotype [13, 14, 16–19]. Interestingly, it has been addressed
that correcting their high circulating levels of GC various
neuroendocrine and adiposity dysfunctions can be reversed
[16, 18], including the hypertrophy of abdominal white adipo-
cytes [14].
Endocrine and metabolic dysfunctions characterizing
the hypothalamic obese rat phenotype have been largely
revisited by several authors including us; however, whether a
liver shift from carbohydrate to lipid metabolism sustaining
liver/ectopic lipid deposition exists in MSG rats has not been
addressed yet. Therefore, in the present study we examined
whether neonatal MSG treatment later results in hepatic
metabolism dysfunction by analysing local carbohydrate and
lipidmetabolic pathways. In addition, the peripheral concen-
trations of several metabolic-endocrine markers and tissue
insulin sensitivity, oxidative stress (OS), and inflammation
were evaluated.
2. Materials and Methods
2.1. Chemicals and Drugs. Reagents of the purest available
grade were obtained from Sigma Chemical Co. (St. Louis,
MO, USA). Primary antibodies were obtained from Santa
Cruz Biotechnology, Inc. (Santa Cruz, California, USA). The
secondary antibody, peroxidase-conjugated AffiniPure don-
key anti-rabbit IgG, was provided by Dianova (Hamburg,
Germany).
2.2. Experimental Animals. Adult male and female Wistar
rats were allowed to mate in colony cages in a light (lights on
from 07:00 to 19:00 h) and temperature (20–22∘C) controlled
room. Rat chow andwater were available ad libitum. Pregnant
rats were transferred to individual cages. Beginning on day
2 after parturition, newborn male pups were injected i.p.
with either 4mg/g BWMSG (Sigma Chemical Co., St. Louis,
MO) dissolved in sterile 0.9% (w/v) NaCl or 10% (w/v) NaCl
(littermate controls; C) once every two days up to 10 days
of age [14]. Rats were weaned at 21 days of age and housed
(3 rats per cage) in a controlled environment (20–22∘C and
lights on from 07:00 to 19:00 hs) with free availability to rat
Purina chow and water. Thereafter, individual daily body
weight and food intake were recorded until the experiment
day (150 days of age). In each experiment, control (C) and
MSG rats were members of the same litters; however, when
accumulating experiments, each different experiment was
performed with animals from different litters. On the morn-
ing (between 08:00 and 10:00 h) of the experiment day,
overnight-fasting animals were weighed and euthanized and
trunk blood was collected (into EDTA-coated tubes). The
brain was immediately dissected out in order to check
effectiveness of MSG treatment by macroscopic observation
of degenerated optic nerves (inclusion criteria). Thereafter,
visceral adipose tissue (VAT) pad and the liver were dissected
and weighed. Next, hepatic medial lobes were excised to
perform several other biochemical assays (see below). Ani-
mals were killed by decapitation according to protocols for
animal use, in agreement with NIH Guidelines for care
and use of experimental animals. All experimentation was
approved by our Institutional Animal Care Committee.
2.3. Circulating Metabolites and Insulin Sensitivity Indexes.
Glycemia was measured by the glucose-oxidase GOD-PAP
method (Roche Diagnostics, Mannheim, Germany) and
plasma concentrations of triglycerides, uric acid, and trans-
aminases aspartate aminotransferase (GOT) and alanine
aminotransferase (GPT) were determined by commercial
(enzymatic-colorimetric) assays (Wiener Lab, Argentina).
Peripheral immunoreactive insulin [13], leptin, and corti-
costerone [16] levelswere determined by previously described
specific radioimmunoassays. Lipid peroxidation was est-
imated by measuring TBARS (thiobarbituric acid-reactive
substance) [20]. The amount of TBARS formed was cal-
culated by extinction coefficient of the MDA (malondial-
dehyde)-TBA complex of 1.56 × 105 (mol/L)−1⋅cm−1 and
expressed as pmol of MDA/mg of plasma protein per mL of
plasma, measured with the Bio-Rad Protein Assay kit.
Fasting glycemia and insulin values were used to esti-
mate peripheral insulin resistance by homeostasis model
assessment-insulin resistance (HOMA-IR) [insulin (𝜇UI/
mL) × glycemia (mM)/22.5]. Liver insulin sensitivity index
(LISI) was calculated with the following formula: 𝑘/(fasting
plasma insulin) × fasting glycemia, where 𝑘 = 22.5 × 18 [21].
2.4. Liver Protein Carbonyl Groups and Reduced Glutathione
(GSH). Protein carbonyl and GSH liver contents were deter-
mined as described elsewhere [22]. Briefly, both components
were spectrophotometrically measured (at 366 nm for pro-
tein carbonyl groups and 414 nm for GSH) and results were
expressed in nmol of carbonyl residues per mg of protein
based on the molar extinction coefficient of 21,000M−1 cm−1.
The results of GSH content were expressed in 𝜇mol of –SH
per g of tissue.
2.5. Total RNA Isolation. Total liver RNA was isolated using
the TRIzol Reagent (Gibco-BRL, Rockville, MD, USA) as
previously described [22].The integrity and quality of the iso-
lated RNA were checked by agarose-formaldehyde gel elec-
trophoresis and by measuring the 260/280 nm absorbance
ratio. DNA contamination was avoided by using DNase I
digestion reagent (Gibco-BRL). Reverse transcription-PCR
was performed with SuperScript III (Gibco-BRL) and total
RNA (50 ng) as a template.
2.6. Liver mRNA Expression Levels Using Real-Time PCR
(qPCR). qPCR was performed with a Mini Opticon Real-
Time PCR Detector Separate MJR (Bio-Rad), using SYBR
Green I as fluorescent dye. cDNA (10 ng) was amplified in a
qPCR reaction mixture containing 0.36 𝜇M of each specific
primer, 3mM MgCl
2
, 0.2mM dNTPs, and 0.15 𝜇L Platinum
Taq DNA Polymerase (6U/𝜇L) (Invitrogen). Samples were
first denatured at 95∘C for 3min followed by 40 PCR cycles.
Each cycle comprised a melting step at 95∘C for 30 sec, an
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Table 1: Rat specific primers used for real-time PCR analyses.
GBAN bp
Actb F, 5
󸀠-AGAGGGAAATCGTGCGTGAC-3󸀠 NM 031144 138
R, 5󸀠-CGATAGTGATGACCTGACCGT-3󸀠
Chrebp F, 5
󸀠-CAGATGCGGGACATGTTTGA-3󸀠 NM 133552.1 205
R, 5󸀠-AATAAAGGTCGGATGAGGATGCT-3󸀠
Fas F, 5
󸀠-GTCTGCAGCTACCCACCCGTG-3󸀠 NM 017332.1 214
R, 5󸀠-CTTCTCCAGGGTGGGGACCAG-3󸀠
Fk F, 5
󸀠-ACGGATCGCAGGTGCCTAT-3󸀠 NM 031855.3 68
R, 5󸀠-AGCACAGTGCAGGAGTTGGA-3󸀠
Gck F, 5
󸀠-GTGTACAAGCTGCACCCGA-3󸀠 NM 012565.1 156
R, 5󸀠-CAGCATGCAAGCCTTCTTG-3󸀠
Gpat F, 5
󸀠-GACGAAGCCTTCCGAAGGA-3󸀠 AF 021348 68
R, 5󸀠-GACTTGCTGGCGGTGAAGAG-3󸀠
G6pase F, 5
󸀠-GATCGCTGACCTCAGGAACGC-3󸀠 NM 013098.2 198
R, 5󸀠-AGAGGCACGGAGCTGTTGCTG-3󸀠
G6pdh F, 5
󸀠-TTCCGGGATGGCCTTCTAC-3󸀠 NM 017006.2 81
R, 5󸀠-TTTGCGGATGTCATCCACTGT-3󸀠
Il1b F, 5
󸀠-ACAAGGAGAGACAAGCAACGAC-3󸀠 NM 031512.2 140
R, 5󸀠-TCTTCTTTGGGTATTGTTTGGG-3󸀠
Pai1 F, 5
󸀠-CCACGGTGAAGCAGGTGGACT-3󸀠 NM 012620.1 195
R, 5󸀠-TGCTGGCCTCTAAGAAGGGG-3󸀠
Pepck F, 5
󸀠-TGCCCCAGGAAGTGAGGAAG-3󸀠 NM 198780.3 177
R, 5󸀠-GGTCAGTGAGAGCCAGCCAAC-3󸀠
Pfk2 F, 5
󸀠-CGATCTATCTACCTATGCCGCCAT-3󸀠 NM 012621.4 256
R, 5󸀠-ACACCCGCATCAATCTCATTCA-3󸀠
Srebp1c F, 5
󸀠-TTTCTTCGTGGATGGGGACT-3󸀠 XM 213329.5 208
R, 5󸀠-CTGTAGATATCCAAGAGCATC-3󸀠
Tnfa F, 5
󸀠- GGCATGGATCTCAAAGACAACC-3󸀠 NM 012675.3 130
R, 5󸀠- CAAATCGGCTGACGGTGTG-3󸀠
F: forward primer; R: reverse primer; GBAN: GenBank accession number; amplicon length, in bp.
annealing step at 65∘C for 30 sec, and an extension step
at 72∘C for 45 sec followed by a final extension at 72∘C
for 10min. Specific oligonucleotide primers (Invitrogen) are
shown in Table 1. Amplicons were designed in a size range
of 90 to 250 bp, with Actinb used as housekeeping gene.
Purity and specificity of amplified PCRproductswere verified
by performing melting curves generated at the end of each
PCR. Data are expressed as relative gene expression after
normalization to Actinb using Qgene96 and LineRegPCR
software.
2.7. Western Blot Analysis. Immunodetection of glucokinase
(GCK), fructokinase (FK), phosphofructokinase-2 (PFK2),
and ACTINB was performed with liver homogenates from
each experimental group. Protein concentration was quanti-
fied by the Bio-Rad Protein Assay kit. Thereafter, dithiothre-
itol and bromophenol blue were added (final concentrations
100mM and 0.1% w/v, resp.). Aliquots of 20𝜇g for GCK and
100 𝜇g for PFK2 of whole protein were placed in reducing
10% (w/v) SDS-PAGE and electroblotted to polyvinylidene
difluoride membranes. ACTINB density was used to nor-
malize protein content: the relative content of target protein
was divided by the relative ACTINB protein level in each
group. Nonspecific binding sites of membranes were blocked
by overnight incubation with nonfat drymilk at 4∘C. Enzyme
identification and quantification were performed with spe-
cific primary antibodies against FK and GCK (final dilution
of 1 : 2000) [22] for 90min, PFK2 antibody (final dilution of
1 : 10000) for 16 hours [23], and ACTINB antibody (final dilu-
tion of 1 : 10000) for 60min. After the respective incubation
period,membranes were rinsed in TBS and further incubated
(1 h) with the corresponding secondary antibody: for GCK
and PFK2, anti-sheep IgG streptavidin-peroxidase conjugate
and anti-chicken IgY peroxidase-labelled were used, respec-
tively, and for ACTINB biotinylated anti-mouse IgG was
used.Diaminobenzidine (DAB, SigmaCo.)was used for color
development. Bands were quantified by densitometry using
Gel-Pro Analyser software.
2.8. Glucokinase Activity. Freshly removed liver pieces were
immediately homogenized in hand-held homogenizers (20
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times) containing ice cold phosphate saline buffer, with
0.1mM PMSF, 0.1mM benzamidine, 2mM DTT, 4 𝜇g/mL
aprotinin, and 0.3M sucrose (pH 7.5). Homogenates were
then passed through a 23-gauge needle syringe (5 times) to
ensure appropriate sample mixing. Aliquots of homogenates
were centrifuged at 600×g to separate and discard the
nuclear fraction. Supernatants were centrifuged at 8,000×g
and 100,000×g at 4∘C, collected, and identified as cytosolic
fractions. Phosphorylation in the 100,000×g soluble cytosolic
fractions was measured at 37∘C, pH 7.4, by recording increas-
ing absorbance (measured at 340 nm) in a well-established
enzyme-coupled photometric assay containing glucose-6-
phosphate dehydrogenase (G6PDH), ATP, and NADP [23].
For each assay, five different experiments were performed in
triplicate. GCK activity was calculated by subtracting activity
measured at 1mM glucose (hexokinase) from that measured
at 100mM glucose. Enzyme activity was then expressed in
mUpermilligramof protein. One unit of enzyme activity was
defined as 1 𝜇mol glucose-6-phosphate formed from glucose
and ATP per minute at 37∘C.
2.9. Glucose-6-Phosphatase (G6Pase) Activity. Homogeniza-
tion of liver samples and isolation of local microsomes were
done as described by Nordlie and Arion [24]. Briefly, the
homogenization medium was 0.25M sucrose/5mM Tris-
acetate/0.5mM Na-EDTA, pH 7.4 (3mL per g of tissue).
Microsomes were washed once with 0.25M sucrose/5mM
Tris-acetate, pH 7.4, and centrifuged at 100,000×g. Untreated
microsomes were diluted to the desired final concentration
with the sucrose buffered solution and then assayed without
any other further treatment. Fully disrupted microsomes
were prepared at 0∘C by adding 0.1mL of 0.75% (w/v) Triton
X-100 and 0.9mL of untreated microsomes (containing
approximately 10mg of protein) and allowed to stand in an
ice bath for 20min. The reaction was stopped by adding
250𝜇L of 10% (w/v) TCA and 2mL of MoNH
4
(diluted in
H
2
SO
4
1 N) plus 320 𝜇L of FeSO
4
(diluted in H
2
SO
4
0.15N)
to 200𝜇L of sample. The OD at 660 nm was determined
photometrically and results were expressed as “latency.”
Latency was calculated by the following formula: 100 ×
(activity measured in disrupted microsomes minus activity
measured in untreated microsomes)/activity measured in
disrupted microsomes [25].
2.10. Fructokinase Activity. Pieces of liver were homogenized
in buffer containing 25mM HEPES (pH 7.1), 100mM KCl,
1mM DTT, and 0.1mM EDTA and spun at 10,000×g at 4∘C
for 20min.Wemeasured FK activity by using a coupled enzy-
matic assay based on existing methods [26]. Briefly, 20 𝜇L
of the sample was added to 200𝜇L of the reaction mixture
containing 25mM HEPES (pH 7.1), 6mM MgCl
2
, 25mM
KCl, 10mM NaF, 5mM D-fructose, 0.2mM NADH, 1mM
phosphoenolpyruvate, 40U/mL pyruvate kinase, 40U/mL
lactate dehydrogenase, and 50mM N-acetyl-D-glucosamine
(to inhibit hexokinase activity). The reaction was started
by adding 10 𝜇L of ATP (5mM final concentration) and
quantitatively measured according to changes in optical
density at 340 nm (30min).
Table 2: Body weight (BW), daily food intake, wet tissue (visceral
adipose tissue, VAT, and liver), and mass and peripheral levels of
several biomarkers in control (C) and MSG rats.
C MSG
Body weight (g) 404.6 ± 9.1 349.3 ± 7.6∗
Food intake (g/day) 20.81 ± 1.95 15.61 ± 0.87∗
VAT mass (g) 4.47 ± 0.88 14.18 ± 1.77∗
Liver weight (g/100 g BW) 3.19 ± 0.07 2.93 ± 0.06∗
Glycemia (g/L) 1.06 ± 0.02 1.17 ± 0.03
Insulin (ng/mL) 0.81 ± 0.05 1.37 ± 0.19∗
Leptin (ng/mL) 1.39 ± 0.37 16.49 ± 2.38∗
Triglycerides (g/L) 1.06 ± 0.07 1.85 ± 0.18∗
Uric acid (mg/dL) 1.19 ± 0.09 1.82 ± 0.22∗
Corticosterone (𝜇g/dL) 6.19 ± 0.98 13.75 ± 1.12∗
GOT (U/L) 75.5 ± 3.2 96.9 ± 5.8∗
GPT (U/L) 9.51 ± 0.69 15.49 ± 1.19∗
Values are means ± SEM. ∗𝑃 < 0.05 versus C values (𝑛 = 12 rats per group).
2.11. Statistical Analysis. Statistical analysis was performed
by ANOVA, followed by Dunnett’s test for multiple compar-
isons with the Prism analysis program (GraphPad). Bartlett’s
test was used to assess variance homogeneity. Results were
expressed as means (±SEM) of the indicated number of
observations; differences were considered significant when 𝑃
was less than 0.05 [22].
3. Results
3.1. The MSG Rat Phenotype. On the experimental day,
MSG rats showed degenerated optic nerves (macroscopic
observation) and other characteristics of this model, such as
(a) low body weight, (b) high visceral adipose tissue mass,
and (c) hypophagia (average of individual daily food intake
between 60 and 150 days of age), thus confirming several
features of the completeMSGphenotype (Table 2).Moreover,
relative wet liver weight (expressed as individual liver weight
per 100 g body weight) was also significantly (𝑃 < 0.05 versus
C rats) reduced in MSG rats (Table 2).
3.2. Circulating Metabolites and Insulin Sensitivity Indexes.
MSG rats had significantly (𝑃 < 0.05 versus C rats)
higher plasma insulin and triglyceride levels, despite similar
glycemia (Table 2). Uric acid levels inMSG animals also were
higher (𝑃 < 0.05 versus C values), as well as those of GOT
and GPT. These altered parameters are clearly indicative of
liver dysfunction (Table 2). Regarding two specific peripheral
markers in this animal model, leptin and corticosterone con-
centrations, we found both hormones several times higher
(𝑃 < 0.05 versus C values) in MSG rats (Table 2).
Finally, after calculation, HOMA-IR and LISI values were
significantly (𝑃 < 0.05) higher and lower, respectively, in
MSG (11.35±0.98 and 1.99±0.19, resp.) than in C (5.35±0.46
and 3.24 ± 0.31, resp.) animals (𝑛 = 12 rats per group).
3.3. Peripheral and Liver Oxidative Stress Markers. Circu-
lating levels of TBARS, a marker of peripheral OS, were
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Figure 1: Liver mRNA levels of Il1b, Tnfa, and Pai-1 (panels (a), (b), and (c), resp.) in control (white bars) and MSG rats (black bars). Results
aremeans± SEM (𝑛 = 8 rats per group). ∗𝑃 < 0.05 versus control values. Statistical analysis was performed by ANOVA, followed byDunnett’s
test for multiple comparisons.
significantly (𝑃 < 0.05 versus C values) higher in MSG
animals (Table 3). Concordant with this finding, liver content
of protein carbonyl groups also was significantly (𝑃 < 0.05
versus C) higher in MSG rats (Table 3), whereas the local
amount of GSH, a peptide highly protective against OS
development, was significantly (𝑃 < 0.05 versus C) lower in
MSG rats (Table 3).
3.4. Neonatal MSG Treatment Resulted in Liver Inflammation
and Dysmetabolism. The livers from MSG rats displayed
a significant (𝑃 < 0.05 versus C values) increase in the
mRNA levels of Il1b, Tnfa, and Pai-1 (Figures 1(a), 1(b), and
1(c), resp.), all key signals indicative of local inflammatory
process.
Although no group difference was observed in hepatic
glycogen content (data not shown), MSG livers showed a
significantly higherGckmRNA expression (1.77±0.31 versus
Table 3: Peripheral and liver (𝑛 = 12 and 6 specimens per group,
resp.) oxidative stress markers in control (C) and MSG rats.
C MSG
Peripheral TBARS (pmol/mg of protein
per mL of plasma) 40.3 ± 3.6 85.1 ± 15.2
∗
Liver protein carbonyl groups (nmol/mg
of tissue protein) 4.43 ± 0.15 7.81 ± 1.32
∗
Liver GSH (nmol/g tissue) 2.71 ± 0.03 2.05 ± 0.04∗
Values are means ± SEM. ∗𝑃 < 0.05 versus C values.
1.01 ± 0.26AU; 𝑃 < 0.05 versus C; 𝑛 = 8 rats per
group). Moreover, GK protein content and activity were also
significantly (𝑃 < 0.05 versus C) higher in MSG livers (Fig-
ures 2(a) and 2(b), resp.). Tissues from MSG rats displayed
a robust increase (𝑃 < 0.05 versus C) in PFK2 mRNA
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Figure 2: Hepatic protein content and activity levels of GCK (panels (a) and (b), resp.), mRNA levels and protein content of PFK2 (panels
(c) and (d), resp.), and mRNA levels and enzyme activity of G6Pase (panels (e) and (f), resp.) in control (white bars) and MSG-treated rats
(black bars). Results are means ± SEM (𝑛 = 8 rats per group). ∗𝑃 < 0.05 versus control values. Statistical analysis was performed by ANOVA,
followed by Dunnett’s test for multiple comparisons.
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Figure 3: Hepatic G6pdh (panel (a)), Chrebp (panel (b)), and Pepck (panel (c)) gene expression in control (white bars) and MSG-treated rats
(black bars). Results are means ± SEM (𝑛 = 8 rats per group). ∗𝑃 < 0.05 versus control values. Statistical analysis was performed by ANOVA,
followed by Dunnett’s test for multiple comparisons.
expression and protein content (Figures 2(c) and 2(d), resp.);
similarly, G6Pase mRNA expression and activity also were
significantly (𝑃 < 0.05 versus C) higher in MSG tissues
(Figures 2(e) and 2(f), resp.).
The mRNA levels of G6pdh and Chrebp were also signifi-
cantly (𝑃 < 0.05 versus C) increased in MSG tissues (Figures
3(a) and 3(b), resp.), despite no group difference in that of
phosphoenolpyruvate carboxykinase (Pepck) (Figure 3(c)).
Finally, regarding the lipogenic pathway, FK mRNA
expression and protein content were significantly (𝑃 < 0.05
versus C values) augmented in MSG tissues (1.93 ± 0.16
versus 1.02 ± 0.12AU and 4.69 ± 0.58 versus 2.11 ± 0.49AU,
resp.; 𝑛 = 8 rats per group). Interestingly, FK activity
was drastically (𝑃 < 0.05 versus C) reduced in livers
fromMSG animals (Figure 4(a)).Moreover, liver lipogenesis-
related genes expressions were modified by the neonatal
MSG treatment; indeed the liver mRNA expression levels of
Srebp1c, Fas, andGpat were 2-fold higher (𝑃 < 0.05 versus C)
in MSG tissues (Figures 4(b), 4(c), and 4(d), resp.).
4. Discussion
The hypothalamus is a key brain structure in charge of the
control of energy balance, and its injury is a major cause
of neuroendocrine (hypothalamic) obesity development
[27]. Conspicuous neuronal loss at the hypothalamic level
can certainly be induced by the neonatal administration
of MSG [28]. As mentioned above, in adult age, MSG-
damaged rats have already installed hypophagy, low body
weight, hyperinsulinemia, hyperleptinemia, hyperuricemia,
hyperadiposity, inflammation, and increased plasma levels
of corticosterone, TBARS, and lipids [19, 29]. In the present
study we were able to find that neonatal MSG treatment
induced a wide neuroendocrine-metabolic alteration once
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Figure 4: Liver FK activity (panel (a)), mRNA levels of Srebp1c (panel (b)), Fas (panel (c)), and Gpat (panel (d)) in control (white bars) and
MSG rats (black bars). Results are means ± SEM (𝑛 = 8 rats per group). ∗𝑃 < 0.05 versus control values. Statistical analysis was performed
by ANOVA, followed by Dunnett’s test for multiple comparisons.
adult age was reached. It must be borne in mind that one
of the expected consequences of neonatal MSG treatment
in rats is the development of stunted growth, thus reaching
adult age with a paradoxical phenotype characterized by
hyperadiposity [13, 14, 16–19] and decreased body and several
tissues weights [3]. Chronic excess of endogenous GC, in
turn, will induce protein breakdown (chronic hypercatabolic
state), thus resulting in hyperuricemic phenotype [30]. Both
metabolic and Cushing’s syndrome human phenotypes [30,
31] share hyperuricemia, and it has been claimed that this
high uric acid peripheral level may have a key pathogenic
role in several metabolic syndrome phenotypes [32], because,
among others, uric acid peripheral levels correlate well
with those of insulin and triglycerides in fructose-induced
metabolic syndrome and, interestingly, correcting the IR state
the hypertriglyceridemia and hyperuricemia can be over-
ridden [32]. Aside from the disturbances mentioned above,
we determined in this rat phenotype a deeply dysfunctional
liver, as indicated by wet tissue weight, carbohydrate and
lipidmetabolisms, and local increase inOS and inflammatory
markers. It should be stressed that in the adult male MSG rat
no previous integrative hepatic studies on the carbohydrate
and lipid metabolic functions and the inflammatory and OS
processes have been examined.
As shown by the endogenous OS status, the higher
HOMA-IR and lower LISI values, this being the first work
demonstrating the latter, recorded in MSG animals clearly
indicate that these rats developed OS-related peripheral and
liver IR. However, it remains to be precisely ascertained
whether long-term exposure to high circulating leptin levels
[14] could be a key cooperative factor for the establishment of
an overall IR state [13, 28], namely, at the liver level. It is also
plausible that, as occurred at the adrenal level [13, 16], liver IR
could be reversed by correcting endogenous overproduction
of glucocorticoid and leptin.
High glucocorticoid treatment is known to induce cell
inflammation and to enhance OS in hepatocytes by increas-
ing and decreasing total oxidative and antioxidant capacities,
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respectively [33]. High OS in theMSG liver could result from
endogenous enhanced reactive oxygen species production
and/or deficient antioxidant mechanism [34, 35], conse-
quently designating high OS as a key pathogenic factor in the
initiation and progression of metabolic diseases, including
hepatic steatosis [36] and type 2 diabetes [34, 37]. Strong evi-
dence also indicates that intracellular signals generated byOS
may also induce chronic inflammation together with insulin
resistance in vivo [38, 39]. High fat diet intake in rodents is
able to increase OS at both liver and adipose tissue levels [40],
and Bloch-Damti et al. [41] claimed that local OS increased
IRS-1 and IRS-2 serine phosphorylations, decreased IRS-
1 protein content, and impaired insulin sensitivity in 3T3-
L1 adipocytes. Interestingly, Park et al. [42] also observed
thatMSG administration in rodents reduces liver antioxidant
biomarkers, such as glutathione level and activities of various
antioxidant enzymes, also enhancing local TBARS content.
We found that our MSG rats are dyslipidemic, tallying
with the stimulated liver lipogenic process revealed by ele-
vated expression levels of theirmaster regulator gene, Srebp1c,
as well as their target genes, Fas and Gpat [43]. Although
other authors have reported similar changes in lipogenic
genes [44], we also found an enhanced gene expression and
reduced activity in liver FK, enzyme providing fructose-1-P
that, in turn, renders trioses for entering into triglyceride syn-
thesis. This phenomenon clearly indicates that when needed
substrates are available, local synthesis of triacylglycerols is
expected [45, 46].
It should be considered that, within an insulin-resistant
state scenario, we were able to determine that, in chronic
hypercorticosteronemic MSG rats, similarly to that previ-
ously found in Cushing’s patients [47], the liver high activity
of the two key enzymes, GCK and G6Pase, assures (within
a very active futile cycle) a drastic increase of high glucose
liver content. Although a previous study has reported an
enhanced activity of G6Pase in MSG animals [48], to our
knowledge this is the first report of an active involvement
of GCK, the hepatic glucose sensor, in the changes induced
by MSG. These data are in agreement with and supported
by those indicating that hypercortisolemic-hyperinsulinemic
(IR) patients did not develop hyperglycemia due to their
reduced peripheral glucose uptake [47]. Indeed, our MSG
rats, sharing with those patients the high GC and insulin
peripheral levels among other conditions, were fully able to
maintain a normal glycemia. These data probably indicate
that GC, through a liver glucocorticoid receptor- (GR-)medi-
ated effect [49], could be responsible for further distribution
of the intrahepatic glucose store. In this regard, if glucose did
not enter in the MSG liver glycogenogenic process, indeed
we and other researchers [50] did not notice any group
difference in liver glycogen content. The fact that this cycle
is highly active in our normoglycemicMSG rats suggests that
glucose cycling could be a common feature of the metabolic
syndrome and in nonhyperglycemic Cushing’s syndrome
phenotypes [47, 51]; moreover, the enhanced glucose cycle
activity has been claimed to counteract hyperglycemia in
hyperglycemic Cushing’s syndrome patients [47], ob/obmice
[52], and diabetic rats [53]. Because glucose-6-phosphate
(G6P) is a branching point for glucose fate, it is also plausible
to expect that glucose ismetabolized through either or both of
the following pathways: (a) being channeled into the hexose
monophosphate shunt pathway due to enhanced G6PDH
activity, thereby producing cell reducing power (as NADPH)
later used for hepatocyte lipogenesis and replenishing GSH
pool, hence providing an additionalmechanism to counteract
OS [54], and/or (b) G6P being isomerized to fructose-
6-phosphate (F6P), then oxidized to pyruvate and acetyl-
CoA, and finally entering into the lipid anabolic pathway.
This/these possibility/ies could be reinforced by our finding
of a robust increase in PFK2, a potent cytosolic activator
of GCK [23] in the MSG liver, thus suggesting that, in
this model, there is an active role of the posttranslational
regulatorymechanisms ofGCKactivity. It is known thatGCK
is also expressed in neurons, pituitary cells, pancreatic B-
cells, and enteroendocrine K and L cells [55], an overall cell
network acting as a glucose sensor for maintaining glucose
homeostasis. Therefore, further research focused on the fact
that whether or not the neonatal MSG treatment broadly
impairs this glucose sensor net is required.
MSG treatment also yielded increased liver Chrebp gene
expression, a parameter well correlating with increased
expression of glycolysis-related genes and a key factor in
the activation of promoter genes involved in the lipogenic
process. In fact, Chrebp has been designated as a central link
between these two pathways in hepatocytes [56]. Kabashima
et al. [57] reported that enhanced activity of the hexose
monophosphate shunt pathway leads to intrahepatocyte
increase in xylulose-5-phosphate, which in turn activates
phosphoprotein phosphatase A2, a main activator of Chrebp.
Our results showing high gene expression of G6pdh, a
rate limiting enzyme of the hexose monophosphate shunt
pathway, demonstrate for the first time that the above-
mentioned mechanisms remained fully operative in MSG
animals. Additionally, as mentioned above, we noticed that
FK protein and activity were drastically augmented and
reduced, respectively, in livers from MSG rats. It must be
borne in mind that the liver lipid metabolism in MSG rats
is clearly displaced to enhanced lipogenesis; thus it could be
speculated that, in the postprandial condition any further
liver entry of hexoses, through FK downstream reactions,
could result in dramatic local lipid overproduction because
carbons enter through this pathway bypass glycolysis regu-
latory steps and are then used in the lipogenic process in
a direct and an uncontrolled fashion [45–47]. Therefore, it
could be hypothesized that inhibited liver FK activity could
represent a novel adaptive (protective feedback) mechanism
in the MSG liver against further detrimental overlipogenic
process in hepatocytes (e.g., hepatic steatosis). In spite of
chronic endogenous glucocorticoid excess inMSG rats, it has
been clearly established that white adipocytes isolated from
these rats are partly refractory to dexamethasone-elicited
leptin secretion and that adipocyte GC resistance can be fully
reversed shortly after correction of endogenous GC over-
production [13]. Hence, it is also possible that endogenous
GC-rich environment in MSG rats could be responsible for
liver dysmetabolism [58]. In fact, we recently noticed that,
after three weeks of bilateral adrenalectomy, adult male MSG
rats normalized their plasmatic concentrations of leptin,
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triglyceride, uric acid, and transaminases (data not shown).
However, because MSG animals developed hyperleptinemia
early in life (30 days of age) [14], a detrimental leptin effect
on liver metabolism must not be discarded. In this regard,
it has previously been assessed that livers from DIO mice
are highly susceptible to inflammation, OS, and nonalcoholic
hepatic steatosis development; conversely, leptin KO-DIO
mice are protected from these dysfunctions [59]. It must be
considered that MSG rats also developed an early peripheral
leptin resistance [13], a dysfunction fully reversed after nor-
malization of endogenous GC environment [13]; therefore,
this leptin-resistance condition could be contributing to liver
carbohydrate dysmetabolism. Altogether, our data strongly
suggest that adult, neonatally damaged, MSG rats are able to
remain prediabetic (normal basal glycemia) due to enhanced
entry of glucose into the liver (high glucose cycle activity),
resulting in a relevant glucose contribution to increased liver
lipogenesis and thus local and ectopic lipid deposition.
5. Conclusions
In conclusion, our study clearly supports that, in adult age,
neonatally damaged MSG male rats are overall insulin-
resistant and with increased OS (at both peripheral and
liver levels). These features are accompanied by a dramatic
dysfunction in hepaticmetabolism: enhanced glucose cycling
(GCK/G6Pase activities) and increased pentose phosphate
shunt, together with adaptive changes in FK activity. Indeed,
MSG rats displayed several features characteristic of the
human Cushing’s and metabolic syndrome phenotypes,
including a decreased liver weight, high tissue inflammation,
and local metabolism highly displaced to an increase in lipid
production.
It remains to be determined whether the MSG liver
dysfunction can be ameliorated by correcting endogenous
glucocorticoid [14, 18], insulin [18, 60], and leptin [14, 18]
overproduction. Finally, the risk factor of MSG liver imbal-
ance in the acyl-ceramidase/ceramide [61] cycle, a major
cooperative mechanism responsible for development of hep-
atic steatosis, requires further investigation.
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